News
- Author:
- Michele G. Sullivan
Publish date: April 24, 2018
MADRID – The single, targeted antibiotic was significantly more effective that routine presurgical prophylaxis for this group.
News
- Author:
- Michele G. Sullivan
Publish date: April 24, 2018
BOSTON – The techniques are challenging and require a sure hand with closure techniques.
News
- Author:
- Michele G. Sullivan
Publish date: April 23, 2018
At the AGA Tech Summit, an industry insider shares tips for turning an idea into an enterprise
News
- Author:
- Michele G. Sullivan
Publish date: April 23, 2018
MADRID – Two venerable antibiotics battle it out in simple UTIs, but it’s nitrofurantoin by a knockout.
News
- Author:
- Michele G. Sullivan
Publish date: April 21, 2018
MADRID – Children younger than 12 months who contracted measles were seven times more likely to die of the disease than were children 2 years ...
News
- Author:
- Michele G. Sullivan
Publish date: April 10, 2018
This new way of classifying AD may change the way doctors and patients talk about the disease – and, one day, could change treatment.
News
- Author:
- Michele G. Sullivan
Publish date: April 9, 2018
In addition to supporting cardiac function and inhibiting inflammatory cytokines, these statins appear to exert a direct antimicrobial effect.
News
- Author:
- Michele G. Sullivan
Publish date: April 6, 2018
Anti-TNF alpha antibody biosimilar will enter European markets this year, but won’t be in United States until 2023.
News
- Author:
- Michele G. Sullivan
Publish date: March 30, 2018
The largest-ever appropriation includes a $414 million boost and may be followed by $597 million more next year.
News
- Author:
- Michele G. Sullivan
Publish date: March 30, 2018
The lack of peer review speeds the pace of discovery, but it comes with risks.
News
- Author:
- Michele G. Sullivan
Publish date: March 28, 2018
The first integrated continuous glucose monitor also set a new federal premarket review standard, FDA said.
News
- Author:
- Michele G. Sullivan
Publish date: March 23, 2018
Diagnosing 88% of Alzheimer’s patients in the mild cognitive impairment stage would save $7 trillion over U.S. citizens’ lifetime.
News
- Author:
- Michele G. Sullivan
Publish date: March 22, 2018
BOSTON – “We are beholden to designing the health care experience to really meet the consumers where they are.”
News
- Author:
- Michele G. Sullivan
Publish date: March 22, 2018
Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells.
News
- Author:
- Michele G. Sullivan
Publish date: March 19, 2018
The in vitro success has launched a phase 2 trial recruiting 152 patients.
